Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act
PLOS Medicine · 2024
DOI: 10.1371/journal.pmed.1004381 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Medicine, 2024. Verfasst von Robin Feldman. Beteiligte Einrichtung: University of California Law, San Francisco, California, United States of America. Hauptthemen laut MEDLINE: Intellectual Property, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California Law, San Francisco, California, United States of America.
ORCID-Profile: Robin Feldman
Zitieren
APA
Feldman, R. (2024). Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004381
Vancouver
Feldman R. Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act. PLOS Medicine. 2024. doi:10.1371/journal.pmed.1004381
BibTeX
@article{Feldman2024,
author = {Feldman, Robin},
title = {Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act},
journal = {PLOS Medicine},
year = {2024},
doi = {10.1371/journal.pmed.1004381}
}
EUVIMED